WO2005063234A2 - VERWENDUNG EINES EFFEKTOR DES GLUTATHIONMETABOLISMUS ZUSAMMEN MIT α-LIPONSÄURE ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN - Google Patents
VERWENDUNG EINES EFFEKTOR DES GLUTATHIONMETABOLISMUS ZUSAMMEN MIT α-LIPONSÄURE ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN Download PDFInfo
- Publication number
- WO2005063234A2 WO2005063234A2 PCT/EP2004/014687 EP2004014687W WO2005063234A2 WO 2005063234 A2 WO2005063234 A2 WO 2005063234A2 EP 2004014687 W EP2004014687 W EP 2004014687W WO 2005063234 A2 WO2005063234 A2 WO 2005063234A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipoic acid
- use according
- prodrugs
- thiol
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the use of at least one effector of glutathione metabolism together with ⁇ -lipoic acid, its salts and / or its prodrugs for simultaneous, separate or chronologically graded cytoprotective treatment of chronic obstructive pulmonary diseases.
- COPD chronic obstructive pulmonary diseases
- Chronic lung obstructions that have become manifest are usually not causally treatable. Treatment must be based on the greatest possible reduction in symptoms. These include secretolysis and bronchodilation. With the exception of lighter forms, accompanying anti-inflammatory therapy with corticosteroids is imperative.
- the fine regulation of the thiol disulfide status is one of the most important basic prerequisites for biological metabolism.
- the central regulatory element within this system is the tripeptide glutathione, which reaches relatively high concentrations (up to 10 raM) in a reduced form.
- SH (thiol) group-bearing proteins are intracellular and, in particular in cell membrane-bound form, further important building blocks of the thiol disulfide status of the cell.
- the metabolism of disulfide cleavage and thiol group formation which is regulated by different enzyme classes, is essential for every normal cell function due to the diversity of its biological functions, including in cellular growth and differentiation processes including programmed cell death as well as cell protection and detoxification mechanisms. Disorders in this system and changes in the concentration of the thiols lead to serious cellular dysfunctions, which remain localized only in individual cases, but usually affect the whole organism.
- DE 101 25 832 describes studies in the context of diabetes mellitus, in which a shift in the redox state to Lasen reduced glutathione as well as an absolute reduction in the total pool of glutathione could be demonstrated. This disorder can be remedied by a combination of ⁇ -lipoic acid and prosthioles.
- the use of at least one effector of glutathione metabolism together with ⁇ -lipoic acid, its salts and / or its prodrugs for simultaneous, separate or temporally classified cytoprotective treatment for chronic obstructive pulmonary disease.
- the restitution of the thiol status of the immune cells was accompanied by a normalization of phagocytosis activity as an expression of a regulation of central functional parameters.
- the combinations of ⁇ -lipoic acid used according to the invention with an effector of glutathione metabolism can be administered prophylactically as well as therapeutically in the usual pharmacological dosage forms or as an instillate.
- the effective dose is case-based determined and is preferably in the range between 30 and 1800 mg / d and particularly preferably between 200 and 600 mg / d ⁇ -lipoic acid.
- the dose of ambroxol, its salts and / or its prodrugs for human medical application in the patient is preferably in the range between 7.5 and 90 mg / d and particularly preferably between 60 and 75 mg / d.
- Ambroxol is used in various dosage forms for lung and bronchial diseases as an expectorant drug.
- the effect of ambroxol as a mucolytic is based on stimulation of the
- silibinin is used as the effector of the glutathione metabolism.
- the dose of silibinin, its salts and / or its prodrugs for human medical application is preferably between 20 and 1600 mg / d and particularly preferably between 300 and 800 mg / d in the patient.
- Silibinin is a representative of naturally occurring polyhydroxyphenylchromanone compounds, which are known as flavolignans. Described within the group of flavolignans silymarin as an extract of milk thistle fruits. In turn, silymarin is a complex of the flavonoids silibines, silichristin, silidianin and bitter substances. As described in DE 35 37 656, silibinin including the positional isomers can be isolated from this complex.
- the drug described can be administered internally, orally or parenterally.
- the drug may take the form of an aerosol, e.g. as dust, mist, spray or inhalation aerosol, a solution, a granulate, a powder, an emulsion, a tablet and / or a film tablet.
- the medicament can preferably contain further additives selected from the group of aqueous solvents,
- Stabilizers suspending, dispersing and wetting agents included.
- the effector of glutathione metabolism and ⁇ -lipoic acid can both be used in one
- the established normal alveolar macrophage cell line CRL 21-92 (NR8383 [AgCllx3A; NR8383.1]) was used.
- the cells were taken up in special cell culture media and incubated in a gassing incubator at 37 ° C, a relative humidity of 98% and 5% relative air-CO 2 content.
- these were artificially thiol-depleted. This was done by cultivation in thiol deficient media (TDM) according to proven methods [Free Radic Biol Med 2000; 29: 1160 to 1165].
- Comparative cultures using full media (RPMI 1640) served to define the best possible normal value under culture conditions.
- CMFDA 5-chloromethylfluorescein diacetate
- membrane-bound thiol groups were also determined by flow cytofluorimetry.
- CTMR Chloromethyltetramethylrhodamine
- CTMR [%] MW ⁇ SD MW + SD MW + SD MW + SD
- Immoirtalized alveolar macrophages were artificially thiol-depleted in the experimental setup described in Example 1.
- the influence of the substances used according to the invention was checked over a period of 96 hours by measuring the intracellular thiol content and the membrane expression of thiols. It was shown that starting after 24 hours, the combination of ⁇ -lipoic acid and silibin in a narrow concentration range around 70 ⁇ g / ml initiated complete restitution of the thiol status of the alveolar macrophages. As shown in Table 3, significant increases in the thiol content were demonstrated over the entire investigation period for this sibinine dose. The sole effect of ⁇ -lipoic acid was regularly significantly exceeded. Lower additive concentrations of silibinin also induced thiol restitution after a longer treatment period.
- Alveolar macrophages were isolated from the bronchoalveolar lava fluid from COPD patients, taken up in cell culture medium and incubated in a fumigation incubator at 37 ° C., a relative air humidity of 98% and 7.5% relative air-CO 2 content.
- a fraction was tion treated with ⁇ -lipoic acid, the effector of ambroxol glutathione metabolism or with the combination of ⁇ -lipoic acid / ambroxol, while a further fraction was carried out as an untreated control.
- Untreated alveolar macrophages from healthy, non-COPD patients served as a normal comparison
- Lipoic acid and A.mbroxol are shown in the time kinetics over 96 hours in relation to healthy people.
- alveolar macrophages from COPD patients were each treated with o-lipoic acid, the effector silibinin or with the combination of ⁇ -lipoic acid / silibinin, while in each case another fraction was carried out as an untreated control.
- Untreated alveolar macrophages from healthy, non-COPD patients also served as a normal comparison.
- the cellular thiol status was determined using the measurement method described under 1.
- Table 6 shows the effect of the combination of ⁇ -lipoic acid and silibinin in the time kinetics over 96 hours in relation to healthy people.
- the phagocytosis ability was selected as a measurand.
- Alveolar macrophages were isolated analogously to the procedure described in Example 3 and cultivated ex vivo.
- the phagocytic performance was determined by a cytofluorimetric test on individual cell level.
- the macrophages were co-cultivated with opsonized and fluorochrome-labeled bacteria.
- the amount of bacteria ingested in a defined period of time was recorded quantitatively via the fluorescence intensity in the macrophages and was considered a measure of their phagocytosis capacity.
- the influence of the combinations used according to the invention on the phagocytosis ability of the peritoneal macrophages after a treatment period of up to 96 hours is shown in Table 7.
- the phagocytosis rate was unchanged compared to the untreated control.
- a significant increase in the phagocytosis rate was achieved using the combination of ⁇ -lipoic acid and ambroxol, which corresponded to the values of the healthy control group after 72 hours.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006546083A JP4838728B2 (ja) | 2003-12-23 | 2004-12-23 | 慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも1つのグルタチオン代謝のエフェクターの使用 |
DE502004005167T DE502004005167D1 (de) | 2003-12-23 | 2004-12-23 | Verwendung von silibinin mit alpha-liponsäure zur behandlung chronisch obstruktiver lungenerkrankungen |
US10/584,072 US20070212339A1 (en) | 2003-12-23 | 2004-12-23 | Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung Diseases |
EP04804278A EP1699451B1 (de) | 2003-12-23 | 2004-12-23 | Verwendung von silibinin mit alpha-liponsäure zur behandlung chronisch obstruktiver lungenerkrankungen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10360954.7 | 2003-12-23 | ||
DE10360954A DE10360954B3 (de) | 2003-12-23 | 2003-12-23 | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005063234A2 true WO2005063234A2 (de) | 2005-07-14 |
WO2005063234A3 WO2005063234A3 (de) | 2005-09-22 |
Family
ID=34716197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/014687 WO2005063234A2 (de) | 2003-12-23 | 2004-12-23 | VERWENDUNG EINES EFFEKTOR DES GLUTATHIONMETABOLISMUS ZUSAMMEN MIT α-LIPONSÄURE ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070212339A1 (de) |
EP (1) | EP1699451B1 (de) |
JP (1) | JP4838728B2 (de) |
AT (1) | ATE374608T1 (de) |
DE (2) | DE10360954B3 (de) |
ES (1) | ES2294567T3 (de) |
WO (1) | WO2005063234A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9084803B2 (en) | 2007-06-29 | 2015-07-21 | Board Of Trustees Of Northern Illinois University | Therapeutic uses of glutathione mimics |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972993A (en) * | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
WO1999055326A1 (en) * | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
WO2001068069A2 (en) * | 2000-03-15 | 2001-09-20 | King's College London | Pharmaceutical composition comprising paracetamol |
US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
WO2002096398A2 (de) * | 2001-05-28 | 2002-12-05 | Esparma Gmbh | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus |
WO2002096414A1 (de) * | 2001-05-28 | 2002-12-05 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie |
EP1442743A1 (de) * | 2003-01-28 | 2004-08-04 | KeyNeurotek AG | Alpha-Liponsäure, Ambroxol und/oder Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3537656A1 (de) * | 1984-11-22 | 1986-05-22 | Dr. Madaus GmbH & Co, 5000 Köln | Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin |
US6495170B1 (en) * | 2000-08-16 | 2002-12-17 | N. V. Nutricia | Method of increasing the presence of glutathione in cells |
GB0129395D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
-
2003
- 2003-12-23 DE DE10360954A patent/DE10360954B3/de not_active Expired - Fee Related
-
2004
- 2004-12-23 DE DE502004005167T patent/DE502004005167D1/de active Active
- 2004-12-23 EP EP04804278A patent/EP1699451B1/de not_active Not-in-force
- 2004-12-23 ES ES04804278T patent/ES2294567T3/es active Active
- 2004-12-23 JP JP2006546083A patent/JP4838728B2/ja not_active Expired - Fee Related
- 2004-12-23 US US10/584,072 patent/US20070212339A1/en not_active Abandoned
- 2004-12-23 WO PCT/EP2004/014687 patent/WO2005063234A2/de active IP Right Grant
- 2004-12-23 AT AT04804278T patent/ATE374608T1/de active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972993A (en) * | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
WO1999055326A1 (en) * | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
WO2001068069A2 (en) * | 2000-03-15 | 2001-09-20 | King's College London | Pharmaceutical composition comprising paracetamol |
US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
WO2002096398A2 (de) * | 2001-05-28 | 2002-12-05 | Esparma Gmbh | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus |
WO2002096414A1 (de) * | 2001-05-28 | 2002-12-05 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie |
EP1442743A1 (de) * | 2003-01-28 | 2004-08-04 | KeyNeurotek AG | Alpha-Liponsäure, Ambroxol und/oder Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
Non-Patent Citations (2)
Title |
---|
BERKSON B M: "A CONSERVATIVE TRIPLE ANTIOXIDANT APPROACH TO THE TREATMENT OF HEPATITIS C COMBINATION OF ALPHA LIPOIC ACID (THIOCTIC ACID), SILYMARIN, AND SELENIUM: THREE CASE HISTORIES" MEDIZINISCHE KLINIK, Bd. 3, 15. Oktober 1999 (1999-10-15), Seiten 84-89, XP000965112 * |
BUHL R ET AL: "ANTIOXIDANTS IN THE TREATMENT OF LUNG DISEASES ANTIOXIDANZIEN ZUR THERAPIE VON LUNGENERKRANKUNGEN" MEDIZINISCHE MONATSSCHRIFT FUER PHARMAZEUTEN, STUTTGART, DE, Bd. 19, Nr. 10, 1996, Seiten 287-294, XP009044433 ISSN: 0342-9601 * |
Also Published As
Publication number | Publication date |
---|---|
ATE374608T1 (de) | 2007-10-15 |
US20070212339A1 (en) | 2007-09-13 |
DE502004005167D1 (de) | 2007-11-15 |
EP1699451A2 (de) | 2006-09-13 |
JP2007534654A (ja) | 2007-11-29 |
WO2005063234A3 (de) | 2005-09-22 |
EP1699451B1 (de) | 2007-10-03 |
ES2294567T3 (es) | 2008-04-01 |
DE10360954B3 (de) | 2005-08-18 |
JP4838728B2 (ja) | 2011-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69924869T2 (de) | Medikament zur behandlung chronisch obstruktiver lungenerkrankung | |
DE60119534T2 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
DE60118019T2 (de) | Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung | |
EP1641442B1 (de) | Verwendung von ectoin und/oder hydroxyectoin zur herstellung von inhalierbaren arzneimitteln sowie eine dies enthaltende inhalationsvorrichtung | |
DE10303229B4 (de) | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen | |
EP1173183A2 (de) | Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel | |
EP1064002B1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
EP1392285B1 (de) | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie | |
DE2349538C2 (de) | Arzneimittel zur Behandlung von Lebererkrankungen | |
DE10360954B3 (de) | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen | |
DE10125882B4 (de) | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus | |
WO2003053445A1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
EP2591777B1 (de) | L-NIL als Inhibitor zur Regeneration der Lunge von an COPD leidenden Patienten | |
DE69735383T2 (de) | Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen | |
DE4319554A1 (de) | Verwendung von etherischen Ölen zur Suppression der Freisetzung von Arachidonsäure | |
EP3426252A1 (de) | Zusammensetzung zur förderung der aktivität von sirtuinen | |
EP0667154A1 (de) | Verwendung von Flavolignanen als Adjuvans in der Tumortherapie. | |
DE10354893B4 (de) | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen | |
DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege | |
DE19903666A1 (de) | Arzneimittel mit einem Gehalt an 3-Isoxazolidinonen und Hydroxylaminsäuren als Wirkstoff und ihre Verwendung | |
WO1997012614A1 (de) | Inhalative applikation von 2-amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol, insbesondere seines (-)-enantiomeren, sowie deren pharmakologisch verträgliche säureadditionssalze | |
EP0910392A2 (de) | Sauerstoffanionradikale enthaltende therapeutische mittel und deren verwendung zur behandlung von morbus parkinson | |
DE102009040870A1 (de) | Modifiziertes kolloidales Edelmetall zur Behandlung und Prophylaxe von Krankheiten | |
DE10331750A1 (de) | Verwendung der Hydrierungsprodukte von Weihrauch (Olibanum) zur Prophylaxe und/oder Behandlung von zerebraler Ischämie, Schädel/Hirntrauma und/oder Alzheimer-Krankheit | |
EP2355815A1 (de) | Verwendung von leukotrien-inhibitoren zur behandlung von lungenerkrankungen bei frühgeborenen kindern |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006546083 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004804278 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004804278 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10584072 Country of ref document: US Ref document number: 2007212339 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10584072 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004804278 Country of ref document: EP |